0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Protein > PLAU > PLU-H5229

Human PLAU / uPA Protein, His Tag

Order Now

  • Synonym
    Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD
  • Source
    Human PLAU, His Tag(PLU-H5229) is expressed from human 293 cells (HEK293). It contains AA Ser 21 - Leu 431 (Accession # NP_002649.1).
    Predicted N-terminus: Ser 21
  • Molecular Characterization
    PLAU Structure

    Human PLAU, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 47.2 kDa. The protein migrates as 45-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    Please note that the protein is not activated by protease digestion. In vitro activation is generally recommended for higher activity.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >92% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Sodium Acetate, 100 mM NaCl, pH5.0 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
PLAU SDS-PAGE

Human PLAU, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 92%.

Bioactivity-ELISA
 PLAU ELISA

Immobilized Human PLAU, His Tag (Cat. No. PLU-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human uPAR, His,Avitag (Cat. No. UPR-H82E7) with a linear range of 0.3-5 ng/mL (QC tested).

  • Background
    Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €310.00

Price(EUR) : €2000.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:4 Details
  • Number of Drugs in Clinical Trials:6 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message